AXIM Biotechnologies, Inc. (AXIM)
USD 0.0
(17.65%)
USD 0.0
(17.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -387.5 Thousand USD | 7.13% |
| 2022 | -417.25 Thousand USD | -790.13% |
| 2021 | 60.46 Thousand USD | 477.85% |
| 2020 | -16 Thousand USD | -107.15% |
| 2019 | 223.78 Thousand USD | 19.61% |
| 2018 | 187.1 Thousand USD | 3867.41% |
| 2017 | 4716.00 USD | 104.4% |
| 2016 | -107.07 Thousand USD | -8479.41% |
| 2015 | -1248.00 USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 21.66 Thousand USD | -50.0% |
| 2012 | 43.33 Thousand USD | 333.33% |
| 2011 | 10 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -92.39 Thousand USD | 128.59% |
| 2024 Q1 | -55.02 Thousand USD | 41.39% |
| 2023 FY | -387.5 Thousand USD | 7.13% |
| 2023 Q3 | -97.17 Thousand USD | -0.36% |
| 2023 Q4 | -93.89 Thousand USD | 3.37% |
| 2023 Q1 | -99.35 Thousand USD | -0.08% |
| 2023 Q2 | -96.82 Thousand USD | 2.55% |
| 2022 FY | -417.25 Thousand USD | -790.13% |
| 2022 Q2 | -106.01 Thousand USD | 0.48% |
| 2022 Q4 | -99.27 Thousand USD | 5.83% |
| 2022 Q1 | -106.52 Thousand USD | -2315.16% |
| 2022 Q3 | -105.43 Thousand USD | 0.55% |
| 2021 Q3 | 8127.00 USD | -45.36% |
| 2021 FY | 60.46 Thousand USD | 477.85% |
| 2021 Q1 | 32.64 Thousand USD | 441.62% |
| 2021 Q2 | 14.87 Thousand USD | -54.44% |
| 2021 Q4 | 4809.00 USD | -40.83% |
| 2020 Q1 | 4723.00 USD | -96.34% |
| 2020 Q4 | -9557.00 USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | -16 Thousand USD | -107.15% |
| 2020 Q2 | - USD | -100.0% |
| 2019 Q1 | 12.68 Thousand USD | -92.34% |
| 2019 FY | 223.78 Thousand USD | 19.61% |
| 2019 Q4 | 128.92 Thousand USD | 68.01% |
| 2019 Q3 | 76.73 Thousand USD | 1308.78% |
| 2019 Q2 | 5447.00 USD | -57.04% |
| 2018 Q2 | 5893.00 USD | -53.01% |
| 2018 Q1 | 12.54 Thousand USD | -14.46% |
| 2018 FY | 187.1 Thousand USD | 3867.41% |
| 2018 Q4 | 165.62 Thousand USD | 5331.98% |
| 2018 Q3 | 3049.00 USD | -48.26% |
| 2017 Q2 | 2252.00 USD | 111.09% |
| 2017 Q1 | -20.31 Thousand USD | 79.88% |
| 2017 FY | 4716.00 USD | 104.4% |
| 2017 Q4 | 14.66 Thousand USD | 80.68% |
| 2017 Q3 | 8114.00 USD | 260.3% |
| 2016 Q2 | -841.00 USD | 30.44% |
| 2016 Q4 | -100.96 Thousand USD | -2386.09% |
| 2016 Q1 | -1209.00 USD | 43.5% |
| 2016 FY | -107.07 Thousand USD | -8479.41% |
| 2016 Q3 | -4061.00 USD | -382.88% |
| 2015 Q3 | -11.22 Thousand USD | -192.64% |
| 2015 Q2 | 12.11 Thousand USD | 0.0% |
| 2015 FY | -1248.00 USD | 0.0% |
| 2015 Q1 | - USD | 100.0% |
| 2015 Q4 | -2140.00 USD | 80.93% |
| 2014 Q2 | 7500.00 USD | 200.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q4 | -10 Thousand USD | 0.0% |
| 2014 Q3 | - USD | -100.0% |
| 2014 Q1 | 2500.00 USD | 0.0% |
| 2013 Q4 | - USD | -100.0% |
| 2013 Q2 | 10.83 Thousand USD | 0.0% |
| 2013 Q1 | 10.83 Thousand USD | 459.07% |
| 2013 FY | 21.66 Thousand USD | -50.0% |
| 2013 Q3 | 10.83 Thousand USD | 0.0% |
| 2012 Q1 | 15 Thousand USD | 50.0% |
| 2012 Q3 | 14.55 Thousand USD | -3.0% |
| 2012 Q2 | 15 Thousand USD | 0.0% |
| 2012 FY | 43.33 Thousand USD | 333.33% |
| 2012 Q4 | -3017.00 USD | -120.74% |
| 2011 Q4 | 10 Thousand USD | 83233.33% |
| 2011 FY | 10 Thousand USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | 12.00 USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -15787.7% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 103.31% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -21.281% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.325% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 98.498% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -702.961% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -211.87% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 102.584% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 12591.973% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 103.957% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 689.552% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -1034.703% |
| Mesoblast Limited | -35.16 Million USD | 98.898% |
| Marizyme, Inc. | 457.7 Thousand USD | 184.662% |
| Genus plc | 178.7 Million USD | 100.217% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.176% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 722.732% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 194.474% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -3422.736% |
| ContraFect Corporation | -154 Thousand USD | -151.624% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -675.002% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 604.815% |
| IMV Inc. | -962.29 Thousand USD | 59.732% |
| MultiCell Technologies, Inc. | 49.32 USD | 785787.348% |
| ONE Bio Corp. | 20.12 Million USD | 101.925% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.962% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 892.436% |
| Q BioMed Inc. | -8988.00 USD | -4211.315% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 101.371% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -2412.325% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.874% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 66.055% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 653.573% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -7725.141% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 375.801% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -297.376% |
| GB Sciences, Inc. | -624.00 USD | -61999.519% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -350.436% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.005% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -186198.558% |
| Enzolytics Inc. | 30.7 Thousand USD | 1361.889% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 180.322% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.035% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 24.685% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 162.765% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.095% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -4275.576% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -362.141% |
| Kadimastem Ltd | -630.13 Thousand USD | 38.505% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 139.222% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 104.032% |
| BioStem Technologies, Inc. | 15.42 Million USD | 102.512% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -3174.195% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 319.473% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 319.473% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 128.553% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -1236.21% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 186.103% |
| SYBLEU INC | 11.69 Thousand USD | 3413.107% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 108.409% |
| Bioxytran, Inc. | -8285.00 USD | -4577.139% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -3.888% |
| Neutra Corp. | 14.33 Thousand USD | 2803.181% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -372.562% |
| PureTech Health plc | -1.6 Million USD | 75.827% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 61.298% |
| IXICO plc | 3.27 Million USD | 111.85% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 44.164% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 78.364% |
| CSL Limited | 7.7 Billion USD | 100.005% |
| Cellectis S.A. | 18 Thousand USD | 2252.783% |